Pretzel Therapeutics
CompanyUnited States
Pretzel Therapeutics develops 2 assets, the furthest in phase 2 (PX578 in mitochondrial disorders). Mostly small molecule acting on oxidative phosphorylation, Mitochondrial biogenesis (PGC-1α) and DNA repair; based in the United States.
- 2
- Assets
- Furthest stage
- Phase 2
- Raised
- US$72.5m
- 0
- Trials
- 0
- Signals
Pipeline
2Activates mitochondrial polymerase POLG to increase mtDNA levels and enhance mitochondrial function.
Phase 2, Small molecule, Oxidative phosphorylation, Mitochondrial biogenesis (PGC-1α), mitochondrial disorders, polg-mediated primary mitochondrial disease
Preclinical, SAMHD1, rare/neurological disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Funding rounds and grants1
- People24
- Similar companies6